QUILLIVANT XR
Drug
PFIZER INC.
Total Payments
$174,091
Transactions
6,157
Doctors
3,340
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $14,852 | 929 | 670 |
| 2017 | $159,239 | 5,228 | 3,187 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $97,541 | 6,151 | 56.0% |
| Unspecified | $63,671 | 1 | 36.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $12,800 | 4 | 7.4% |
| Travel and Lodging | $78.82 | 1 | 0.0% |
Payments by Type
General
$110,420
6,156 transactions
Research
$63,671
1 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| DOSE RESPONSE EFFECTS OF QUILLIVANT XR IN CHILDREN WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD AND AUTISM SPECTRUM DISORDER ASD A PILOT STUDY | Pfizer Inc. | $63,671 | 0 |
Top Doctors Receiving Payments for QUILLIVANT XR
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Seattle, WA | $63,671 | 1 |
| Ann Childress | Child & Adolescent Psychiatry | Las Vegas, NV | $6,400 | 2 |
| , MD, PHD | Psychiatry | Somerset, NJ | $6,400 | 2 |
| , M.D | Pediatrics | Lafayette, LA | $224.66 | 19 |
| , M.D | Child & Adolescent Psychiatry | Elgin, IL | $221.88 | 11 |
| , M.D | Pediatrics | Lafayette, LA | $205.28 | 17 |
| , M.D | Pediatrics | Baton Rouge, LA | $193.34 | 12 |
| , M.D | Pediatrics | Lafayette, LA | $190.22 | 15 |
| , M.D | Child & Adolescent Psychiatry | Frisco, TX | $184.19 | 10 |
| , M.D | Pediatrics | New Lenox, IL | $178.25 | 7 |
| , M.D | Psychiatry | San Marcos, CA | $174.67 | 10 |
| , MD | Child & Adolescent Psychiatry | Columbia, MD | $173.78 | 8 |
| , M.D | Pediatrics | Baton Rouge, LA | $173.75 | 10 |
| , MD | Pediatric Allergy/Immunology | Naperville, IL | $161.17 | 8 |
| , MD | Family Medicine | Milwaukee, WI | $160.01 | 7 |
| , M.D | Psychiatry | San Marcos, CA | $158.49 | 9 |
| , M.D | Pediatrics | Tulsa, OK | $148.94 | 9 |
| , M. D | Pediatrics | Tulsa, OK | $148.94 | 9 |
| , M.D | Adolescent Medicine | Houma, LA | $148.42 | 7 |
| , M.D., F.A.A.P | Pediatrics | Lubbock, TX | $147.19 | 8 |
| , MD | Pediatrics | Shorewood, IL | $146.13 | 6 |
| , M.D | Adolescent Medicine | Broken Arrow, OK | $145.33 | 9 |
| , M.D | Psychiatry | Lutherville Timonium, MD | $142.84 | 8 |
| , M.D | Pediatrics | Baton Rouge, LA | $142.33 | 11 |
| , M.D | Pediatrics | Phoenix, AZ | $141.85 | 10 |
Ad
Manufacturing Companies
- PFIZER INC. $110,420
- Pfizer Inc. $63,671
Product Information
- Type Drug
- Total Payments $174,091
- Total Doctors 3,340
- Transactions 6,157
About QUILLIVANT XR
QUILLIVANT XR is a drug associated with $174,091 in payments to 3,340 healthcare providers, recorded across 6,157 transactions in the CMS Open Payments database. The primary manufacturer is PFIZER INC..
Payment data is available from 2017 to 2018. In 2018, $14,852 was paid across 929 transactions to 670 doctors.
The most common payment nature for QUILLIVANT XR is "Food and Beverage" ($97,541, 56.0% of total).
QUILLIVANT XR is associated with 1 research study, including "DOSE RESPONSE EFFECTS OF QUILLIVANT XR IN CHILDREN WITH ATTENTION DEFICITHYPERACTIVITY DISORDER ADHD AND AUTISM SPECTRUM DISORDER ASD A PILOT STUDY" ($63,671).